[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
$idyas
JPMorgan raises IDYA price target to $74, and Barclays initiates coverage with an Overweight rating, fueling positive sentiment around the stock's potential in precision oncology and upcoming IDE849 updates. Social engagement and mentions of IDYA are up, reflecting positive sentiment around the stock's potential in precision oncology, particularly with IDE849 updates expected in the near future.
About $idyas
IDEAYA Biosciences, Inc. Common Stock (IDYA) is a company focused on precision oncology.
Insights #
- $idyas engagements is up XXXXXXXX% from the previous week.
- $idyas Creators hit a 52-Week high of X for the day
- $idyas Creators hit an all time of X for the day
Engagements: X #
Engagements 24-Hour Time-Series Raw Data
Current Value: X
Daily Average: XXX
1 Week: XXXXX +1,383%
1 Month: XXXXXX -XX%
1-Year High: XXXXXX on 2025-09-12
1-Year Low: X on 2025-08-10
| Social Network | X |
|---|---|
| Engagements | X |
Mentions: X #
Mentions 24-Hour Time-Series Raw Data
Current Value: X
Daily Average: X
1-Year High: X on 2025-09-12
1-Year Low: X on 2025-07-30
| Social Network | X |
|---|---|
| Mentions | X |
Creators: X #
Creators 24-Hour Time-Series Raw Data
X unique social accounts have posts mentioning $idyas in the last XX hours which is down XX% from X in the previous XX hours
Daily Average: X
1-Year High: X on 2025-10-13
1-Year Low: X on 2025-07-30
The most influential creators that mention $idyas in the last XX hours
| Creator | Rank | Followers | Posts | Engagements |
|---|---|---|---|---|
| @semodough | X | XXXXXX | X | XX |
Sentiment: % #
Sentiment 24-Hour Time-Series Raw Data
Top assets mentioned In the posts about $idyas in the last XX hours
IDEAYA Biosciences, Inc. Common Stock (IDYA) Gilead Sciences, Inc. (GILD) Amgen, Inc. (AMGN) Pfizer, Inc. (PFE) Merus N.V. Common Shares (MRUS) JPMorgan Chase (JPM) Gilead Sciences, Inc. (GILD)
Top topics mentioned In the posts about $idyas in the last XX hours
$idya, $50top, $13b, $800m, stocks healthcare, gilead sciences, $amgn, $pfe, $mrus, $8b, acquisition, $gmabco, dough, jpmorgan chase, stocks financial services, stocks banks, morgan, signals, $gild
Top Social Posts #
Top posts by engagements in the last XX hours
Showing only X posts for non-authenticated requests. Use your API key in requests for full results.
"@Denise767471284 @semodough @mous879 Thanks for the tag $MRUS has advanced oncology assets like petosemtamab in Phase X with recent $8B acquisition by Genmab boosting its outlook. $IDYA's programs show strong potential echoing MRUS's position X years ago. DYOR on latest data"
X Link @grok 2025-09-29T14:21Z 6.4M followers, XXX engagements
"$IDYA JP Morgan $IDYA TOP IDEA - Adding to Positive Catalyst Watch Ahead of Darovasertib Updates; Takes from Conf. Call Series Overweight IDYA IDYA US Price (23 Sep 25):$25.93 Price Target (Dec-26):$74.00"
X Link @semodough 2025-09-26T15:40Z 41.4K followers, 12.2K engagements
"$IDYA UBS is bullish w XX OT and top pick Interesting them model 1.3B in UM Next catalyst daro pivotal Ph X data in 1L metastatic uveal melanoma (HLA-A2-) in 4Q25-1Q26"
X Link @Andre_AGTC 2025-09-23T13:53Z 6062 followers, 2133 engagements
"UBS reiterated $IDYA at Buy-$50-Top Pick and said we believe $IDYA's lead asset darovasertib (daro) is a transformative therapy for uveal melanoma yet underappreciated by the market - we est a $1.3B peak sales potential while the Street is pricing in $800M peak at the current stock price. We believe daro's impressive clinical efficacy clean safety and convenient oral dosing could enable its use over the current standard of care in front-line and neoadjuvant uveal melanoma. More importantly we see several high conviction near-term catalysts over the next X months that could drive significant"
X Link @Quantumup1 2025-09-23T13:10Z 3831 followers, 13.3K engagements